We are a pioneer in developing novel therapeutics aimed
at treating neurological and neuropsychiatric brain disorders.
30
Jan
GliaCure President Phil Haydon’s research laboratory at Tufts University has published a study showing that glia may provide the key to a novel treatment for depression. It has long been known that a total night of sleep deprivation has a fast-acting antidepressant effect; however, the mechanism underlying this effect was not understood. The Haydon group…more »
16
Dec
In its reports on Latest Science the National Institute of Drug Abuse (NIDA) highlighted an upcoming publication co-authored by GliaCure President Phil Haydon. Haydon and his collaborators at the University of Pennsylvania have discovered that glia likely play a key role in relapse of individuals addicted to cocaine. Glia may thus provide a target for…more »
03
Dec
The New England Journal of Medicine recently included papers detailing research from two groups pointing to a mutation in the gene TREM2 as a risk factor for Alzheimer’s disease. This mutation appears to lead to inflammation of the brain and decreased clearing of amyloid beta plaques. In discussing these papers Harald Neumann and Mark J.…more »
17
Oct
GliaCure President Philip Haydon recently gave a presentation at the BioPharm America 2012 conference in Boston.
02
Oct
During the 2012 BIO International Convention in June GliaCure President Phil Haydon had an interesting conversation with Rob Wright, Chief Editor of Life Science Leader magazine. Phil and Rob talked about how, to be innovative in drug discovery, one often has to ignore established thinking. Based on this conversation, Phil was asked to write an…more »
26
Sep
On Wednesday, October 3 GliaCure President Phil Haydon will be one of four panelists presenting a lunchtime briefing on Capitol Hill titled: “Where Do We Stand With Alzheimer’s Research?” This briefing is intended to give updates on Alzheimer’s research and funding. Phil is participating at the invitation of Massachusetts Congressman Ed Markey’s office. Rep. Markey…more »
17
Sep
GliaCure President Phil Haydon and Vice President Mike Szulczewski will be at the BioPharm America 2012 conference in Boston from September 19 to 21. Phil and Mike will be participating in a range of one-on-one meetings during the conference. Phil Haydon has also been selected to make a Next Generation presentation on Friday, September 21…more »
29
Aug
Time magazine recently reported on a study in the Journal of Neuroscience suggesting that glia, not neurons, are likely key to developing an addiction-proof painkiller.
15
Aug
A recent article in Science Daily references reports on work by Prof. Dr. Carola Haas from the Bernstein Center and Dr. Matthias Kirsch from the Institute of Anatomy and Cell Biology at the University of Freiburg showing that, contrary to previous thinking, glia help to reduce long-term damage brought upon by epileptic fits.
21
Jun
GliaCure’s participation in the 2012 BIO International Convention in Boston was very successful. The booth included a triptych backdrop with the central banner asking, “Are You GliaCurious?” Looping iPad presentations attracted attention and resultant traffic at the booth was great. President Phil Haydon and VP Mike Szulczewski were busy with in-booth meetings with representatives from…more »